EVAX Q2 2025 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000-76.0% YoY

Gross Profit

$37,000100.0% margin

Operating Income

-$4M-11729.7% margin

Net Income

-$5M-13056.8% margin

EPS (Diluted)

$-4.40

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$22M

Total Liabilities

$16M

Stockholders' Equity

$6M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	$154,000	-76.0%
Gross Profit	$37,000	$154,000	-76.0%
Operating Income	-$4M	-$5M	+5.3%
Net Income	-$5M	-$6M	+22.1%